Combinatorial chemistry company Chemicus focuses on bottlenecks in lead optimization in the drug discovery process. Chemicus claims that its abacus system makes larger amounts of similar compounds necessary for evaluating "hits" further down the drug discovery line.
You may also be interested in...
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer
While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.
ASCO 2023 – Elevation follows in Astellas’s slipstream
There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 antibody-drug conjugate, but no such good news for Zai Lab’s zolbetuximab challenger.